Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1984 Oct;58(1):193–198.

Serum IgG levels and complement activity in hypogammaglobulinaemic patients under substitution therapy.

A Plebani, L D Notarangelo, M Duse, A Avanzini, M Massa, A G Ugazio
PMCID: PMC1576950  PMID: 6332693

Abstract

Haemolytic activity of the classical and alternative pathways of complement as well as serum levels of C1q, Factor B, Factor H, C3, C4, C3d,g and IgG were determined in 15 hypogammaglobulinaemic patients on immunoglobulin replacement therapy. Alternative pathway activity (AP) and C1q were defective in the presence of low IgG levels and normalized on achievement of normal IgG levels; for both variables the correlation with serum IgG was highly significant. Classical pathway activity (CP), C3, C4 and Factor H serum levels were normal independently of IgG levels; Factor B and C3d, g serum levels were elevated in hypogammaglobulinaemic patients regardless of IgG levels. The present report supports the hypothesis that IgG serum levels influence complement function.

Full text

PDF
193

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adinolfi M. Human complement C9 and factor B in the diagnosis of infections in infants. Acta Paediatr Scand. 1982 Sep;71(5):845–846. doi: 10.1111/j.1651-2227.1982.tb09531.x. [DOI] [PubMed] [Google Scholar]
  2. Bourke B. E., Moss I. K., Maini R. N. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. J Immunol Methods. 1982;48(1):97–108. doi: 10.1016/0022-1759(82)90214-9. [DOI] [PubMed] [Google Scholar]
  3. Corry J. M., Polhill R. B., Jr, Edmonds S. R., Johnston R. B., Jr Activity of the alternative complement pathway after splenectomy: comparison to activity in sickle cell disease and hypogammaglobulinemia. J Pediatr. 1979 Dec;95(6):964–969. doi: 10.1016/s0022-3476(79)80284-x. [DOI] [PubMed] [Google Scholar]
  4. Gewurz H., Pickering R. J., Christian C. L., Snyderman R., Mergenhagen S. E., Good R. A. Decreased C'-1q protein concentration and agglutinating activity in agammaglobulinaemia syndromes: an inborn error reflected in the complement system. Clin Exp Immunol. 1968 Jun;3(5):437–445. [PMC free article] [PubMed] [Google Scholar]
  5. Hill A. W., Shears A. L., Hibbitt K. G. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum. Immunology. 1978 Jan;34(1):131–136. [PMC free article] [PubMed] [Google Scholar]
  6. Kohler P. F., Müller-Eberhard H. J. Complement-immunoglobulin relation: deficiency of C'1q associated with impaired immunoglobulin G synthesis. Science. 1969 Jan 31;163(3866):474–475. doi: 10.1126/science.163.3866.474. [DOI] [PubMed] [Google Scholar]
  7. Kohler P. F., Müller-Eberhard H. J. Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus. J Clin Invest. 1972 Apr;51(4):868–875. doi: 10.1172/JCI106881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  9. Moore F. D., Jr, Fearon D. T., Austen K. F. IgG on mouse erythrocytes augments activation of the human alternative complement pathway by enhancing deposition of C3b. J Immunol. 1981 May;126(5):1805–1809. [PubMed] [Google Scholar]
  10. Nelson B., Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol. 1979 May;122(5):1994–1999. [PubMed] [Google Scholar]
  11. Nolte M. T., Pirofsky B., Gerritz G. A., Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979 May;36(2):237–243. [PMC free article] [PubMed] [Google Scholar]
  12. Polhill R. B., Jr, Newman S. L., Pruitt K. M., Johnston R. B., Jr Kinetic assessment of alternative complement pathway activity in a hemolytic system. II. Influence of antibody on alternative pathway activation. J Immunol. 1978 Jul;121(1):371–376. [PubMed] [Google Scholar]
  13. Schenkein H. A., Ruddy S. The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan. J Immunol. 1981 Jan;126(1):7–10. [PubMed] [Google Scholar]
  14. Schenkein H. A., Ruddy S. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway. J Immunol. 1981 Jan;126(1):11–15. [PubMed] [Google Scholar]
  15. Schreiber R. D., Morrison D. C., Podack E. R., Müller-Eberhard H. J. Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med. 1979 Apr 1;149(4):870–882. doi: 10.1084/jem.149.4.870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tarr P. I., Hosea S. W., Brown E. J., Schneerson R., Sutton A., Frank M. M. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation. J Immunol. 1982 Apr;128(4):1772–1775. [PubMed] [Google Scholar]
  17. Ugazio A. G., Duse M., Plebani A., Notarangelo L. D., Burgio G. R. Subcutaneous infusion of gamma globulins in the management of agammaglobulinemic patients. Birth Defects Orig Artic Ser. 1983;19(3):213–215. [PubMed] [Google Scholar]
  18. Ugazio A. G., Duse M., Re R., Mangili G., Burgio G. R. Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia. Lancet. 1982 Jan 23;1(8265):226–226. doi: 10.1016/s0140-6736(82)90793-0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES